Doxil Injection, Suspension, Liposomal
Product Images NDC 0338-9665

This text appears to be a chemical structure with the formula and structure of a compound. It includes symbols and chains indicating the presence of hydrogen, carbon, nitrogen, and oxygen atoms. Additionally, the text mentions a certain number as "n=ca. 45", which could possibly represent a molecular count or a variable value related to the compound structure. The compound seems to have complex molecular arrangements involving long carbon chains and various functional groups.*

This text appears to contain chemical equations with symbols and structures of organic compounds. The equations seem to involve carbon, hydrogen, and oxygen atoms. The presence of m and n values indicates variables that are likely related to the structure of the compounds. The compounds may be part of a larger chemical synthesis or reaction process.*

This text mentions a coating named MPEG-DSPE, which encapsulates doxorubicin HCI within an aqueous core. The presence of a liposomal bilayer is also indicated. The combination of these components suggests a drug delivery system that may be used in medical or pharmaceutical applications.*

This is a table showing the progression-free survival data for two groups - one receiving DOXIL and Bortezomib and the other receiving only Bortezomib. The table includes the number of subjects at risk over different time intervals. The p-value for the comparison is provided as less than 0.0001, indicating a statistically significant difference in progression-free survival between the two groups. Additionally, the Hazard Ratio (HR) along with its 95% confidence interval is given as 0.55 (0.43, 0.71), further supporting the efficacy of DOXIL in combination with Bortezomib in improving progression-free survival outcomes.*

This text describes a medication with the NDC 0338-9667-01. It is a liposomal formulation of DOXOrubicin Hydrochloride for intravenous infusion only, with a concentration of 2 mg/mL. Each vial contains 20 mg of the drug in 10 mL and is a single-dose vial that should be refrigerated (2°-8°C) but should not be frozen. The manufacturer is Baxter Healthcare Corporation located in Deerfield, IL, USA. Detailed dosage information can be found in the package insert.*

This is a description of a medication called DOXIL, which is a liposome injection containing doxorubicin hydrochloride. It is intended for intravenous infusion only after dilution with 5% Dextrose Injection, USP. The formulation includes various components such as cholesterol, soy phosphatidylcholine, and polyethylene glycol. It is essential to refrigerate the medication between 2°-8°C (36°-46°F) and not freeze it. DOXIL is a cytotoxic medication and should be discarded if any portion is unused. The product is manufactured for Baxter Healthcare Corporation in Germany and is for prescription use only. It is crucial to refer to the prescribing information for the recommended dosage.*

This text is a description of a medication in liposomal formulation for intravenous infusion. It contains 50 mg in 25 mL (2 mg/mL) and is a single-dose vial. The medication should be refrigerated between 2°-8°C (36°-46°F) and should not be frozen. It is indicated as cytotoxic and should not be substituted for Doxorubicin Hydrochloride. Unused portions should be discarded, and users are advised to refer to the package insert for dosage information. This medication is manufactured by Baxter Healthcare Corporation located in Deerfield, IL, USA.*

This text provides detailed information about a medication called DOXIL, specifically its NDC code, dosage, composition, and administration instructions. DOXIL is a liposome injection used for infusion only after dilution. It contains doxorubicin Hydrochloride, cholesterol, hydrogenated soy phosphatidylcholine, and other components. The medication must be refrigerated between 2°-8°C, and 5% Dextrose Injection should be used for dilution. The text also mentions the manufacturer (Baxter Healthcare Corporation) and provides additional trademarks and legal information related to the product. Additionally, it states that the formulation is liposomal and recommends referring to the prescribing information for the correct dosage.*